Wang Fangqian, Ye Yuxiao, Zhang Zengjie, Teng Wangsiyuan, Sun Hangxiang, Chai Xupeng, Zhou Xingzhi, Chen Jiayu, Mou Haochen, Eloy Yinwang, Jin Xiaoqiang, Chen Liang, Shao Zhenxuan, Wu Yan, Shen Yue, Liu An, Lin Peng, Wang Jianwei, Yu Xiaohua, Ye Zhaoming
Department of Orthopedic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, PR China.
Orthopedics Research Institute of Zhejiang University, Hangzhou City, Zhejiang Province, PR China.
Research (Wash D C). 2023 May 5;6:0086. doi: 10.34133/research.0086. eCollection 2023.
Platelet-derived growth factor-BB (PDGF-BB)/platelet-derived growth factor receptor-β (PDGFR-β) pathway is conventionally considered as an important pathway to promote osteogenesis; however, recent study suggested its role during osteogenesis to be controversial. Regarding the differential functions of this pathway during 3 stages of bone healing, we hypothesized that temporal inhibition of PDGF-BB/PDGFR-β pathway could shift the proliferation/differentiation balance of skeletal stem and progenitor cells, toward osteogenic lineage, which leads to improved bone regeneration. We first validated that inhibition of PDGFR-β at late stage of osteogenic induction effectively enhanced differentiation toward osteoblasts. This effect was also replicated in vivo by showing accelerated bone formation when block PDGFR-β pathway at late stage of critical bone defect healing mediated using biomaterials. Further, we found that such PDGFR-β inhibitor-initiated bone healing was also effective in the absence of scaffold implantation when administrated intraperitoneally. Mechanistically, timely inhibition of PDGFR-β blocked extracellular regulated protein kinase 1/2 pathway, which shift proliferation/differentiation balance of skeletal stem and progenitor cell to osteogenic lineage by upregulating osteogenesis-related products of Smad to induce osteogenesis. This study offered updated understanding of the use of PDGFR-β pathway and provides new insight routes of action and novel therapeutic methods in the field of bone repair.
血小板衍生生长因子-BB(PDGF-BB)/血小板衍生生长因子受体-β(PDGFR-β)通路传统上被认为是促进成骨的重要通路;然而,最近的研究表明其在成骨过程中的作用存在争议。关于该通路在骨愈合三个阶段的不同功能,我们假设对PDGF-BB/PDGFR-β通路进行适时抑制可使骨骼干祖细胞的增殖/分化平衡向成骨谱系转变,从而促进骨再生。我们首先验证了在成骨诱导后期抑制PDGFR-β可有效增强向成骨细胞的分化。当在使用生物材料介导的临界骨缺损愈合后期阻断PDGFR-β通路时,体内也出现了加速骨形成的现象,从而验证了这一效果。此外,我们发现当腹膜内给药时,这种由PDGFR-β抑制剂引发的骨愈合在没有支架植入的情况下也有效。从机制上讲,适时抑制PDGFR-β可阻断细胞外调节蛋白激酶1/2通路,通过上调Smad的成骨相关产物来诱导成骨,从而将骨骼干祖细胞的增殖/分化平衡转向成骨谱系。本研究为PDGFR-β通路的应用提供了新的认识,并为骨修复领域提供了新的作用途径和新型治疗方法。